Mario Eisenberger

Professor

1977 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Castration Medicine & Life Sciences
Survival Medicine & Life Sciences
Androgens Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Suramin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1977 2018

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

Crawford, E. D., Schellhammer, P. F., McLeod, D. G., Moul, J. W., Higano, C. S., Shore, N., Denis, L., Iversen, P., Eisenberger, M. A. & Labrie, F., Jan 1 2018, (Accepted/In press) In : Journal of Urology.

Research output: Contribution to journalArticle

Androgen Antagonists
Androgen Receptors
Prostatic Neoplasms
Castration
Therapeutics

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., Oudard, S., Joly, F., Jarrard, D. M., Soulie, M., Eisenberger, M. J., Habibian, M., Dreicer, R., Garcia, J. A., Hussain, M. H. M., Kohli, M., Vogelzang, N. J., Picus, J., DiPaola, R. & Sweeney, C., Jan 1 2018, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

docetaxel
Prostatic Neoplasms
Androgens
Survival
Therapeutics

Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

Paller, C. J. , Zhou, X. C. , Heath, E. I. , Taplin, M. E. , Mayer, T. , Stein, M. N. , Bubley, G. J. , Pili, R. , Hudson, T. , Kakarla, R. , Abbas, M. M. , Anders, N. M. , Dowling, D. , King, S. , Bruns, A. B. , Wagner, W. D. , Drake, C. G. , Antonarakis, E. S. , Eisenberger, M. A. , Denmeade, S. R. & 3 others Rudek, M. A., Rosner, G. L. & Carducci, M. A., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 306-315 10 p.

Research output: Contribution to journalArticle

Controlled Clinical Trials
Vitis
Prostatic Neoplasms
Placebos
Skin

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

Mehra, N., Dolling, D., Sumanasuriya, S., Christova, R., Pope, L., Carreira, S., Seed, G., Yuan, W., Goodall, J., Hall, E., Flohr, P., Boysen, G., Bianchini, D., Sartor, O., Eisenberger, M. A., Fizazi, K., Oudard, S., Chadjaa, M., Macé, S. & de Bono, J. S., Jan 1 2018, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

Castration
Plasma Cells
Prostatic Neoplasms
DNA
Therapeutics

Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy

Isaacsson Velho, P. & Eisenberger, M. A., May 15 2018, In : Oncology (Williston Park, N.Y.). 32, 5, p. 223-226 4 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Drug Therapy
abiraterone